Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention ISM4808, the most common co-covered peer. The tracked stories average 3 original sources each. TaiGen Biopharmaceuticals appears in 1 tracked Biotech story from March 6, 2026.
Last mentioned: Mar 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention ISM4808, the most common co-covered peer. The tracked stories average 3 original sources each. TaiGen Biopharmaceuticals appears in 1 tracked Biotech story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TaiGen Biopharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Phase I Initiation
First human subject enrolled and dosed in the Phase I clinical trial.
Out-Licensing Deal
TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.
Candidate Discovery
Insilico Medicine identifies ISM4808 using generative AI models.
Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
TaiGen Biopharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
